期刊文献+

单纯疱疹病毒2型临床分离株体外对阿昔洛韦和伐昔洛韦的敏感性测定 被引量:1

In vitro antiviral susceptibilities of HSV-2 clinical isolates to acyclovir and valacidovir
原文传递
导出
摘要 目的 测定南京地区收集的15株单纯疱疹病毒2型(HSV-2)对阿昔洛韦和伐昔洛韦的敏感性,初步建立空斑法提取阿昔洛韦耐药株。方法 Veto细胞培养法分离扩增出临床毒株,直接免疫荧光法分型,并用MTT法测定15株2型毒株对阿昔洛韦、伐昔洛韦的敏感性。体外阿昔洛韦诱导,空斑纯化HSV耐药株。结果 15株临床株对阿昔洛韦和伐昔洛韦的半数病毒抑制质量浓度(IC50)分别为0.0215~0.2799μg/mL(平均0.0766μg/mL),0.0549~0.4575μg/mL(平均0.1605μg/mL)。生殖器疱疹初发组与复发组、用药组与未用药组对2种药物的敏感性采用Wilcoxon秩和检验,P值均〉0.05,差异无统计学意义。从15株HSV-2临床株中未提取到耐药空斑;从HSV-1 Sam实验室标准株提取到一个耐药空斑,MTT法测定阿昔洛韦IC50为13.36μg/mL;从HSV-2333标准株中提取到9个耐药空斑,扩增后MTT法测定其对阿昔洛韦的IC50为1.04~5.08μg/mL。结论 目前在南京地区收集的HSV-2型毒株对阿昔洛韦和伐昔洛韦敏感性较高,尚未发现耐药株。体外药物诱导、空斑纯化能较快提取到HSV耐药株。 Objective To investigate the in vitro susceptibilities of HSV-2 clinical strains isolated in Nanjing to acyclovir ( ACV ) and valaciclovir ( VCV ), and to develop a plaque assay to purify ACV- resistant HSV isolates. Methods HSV-2 strains were isolated in Veto cells from genital herpes lesions of patients attending our STD clinic from May 2005 to November 2005, and typed with monoclonal antibodies by direct immunofluorescence assay. The susceptibilities to ACV and VCV of HSV-2 isolates were determined by MTT assay, To induce drug-resistance, HSV reference and clinical strains were cultured in the presence of ACV ( 5μg/mL ), The ACV resistant strains were isolated by plaque purification. Results A total of 15 HSV-2 strains were isolated from clinical specimens. Their IC50 to ACV and VCV ranged 0.0215 - 0.2799μg/mL ( mean 0.0766 μg/mL ) and 0.0549 - 0.4575 μg/mL ( mean 0.1605 μg/mL ), respectively. No significant differences were found regarding the antiviral susceptibilities between HSV-2 strains isolated from patients with primary infection and those recurrent infection, or between those from patients with previous antiviral treatment and those without antiviral treatment ( both P 〉 0.05 ). No drug-resistant plaque was isolated from the HSV-2 clinical strains. Only one drugresistant plaque was isolated from HSV-1 Sam strain with an IC50 of 13.36μg/mL, and nine from HSV-2 333 swain with an IC50 of 1.04 - 5.08μg/mL. Conclusions All the 15 HSV-2 swains isolated in Nanjing are highly sensitive to acyclovir and valaciclovir, and no drug-resistant swains are found. Antiviral resistant HSV-2 swains can be rapidly obtained by in vitro drug-inducing and plaque purification.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2007年第3期143-145,共3页 Chinese Journal of Dermatology
关键词 疱疹病毒2型 微生物敏感性试验 阿昔洛韦 伐昔洛韦 Herpesvirus 2, human Acyclovir Valaciclovir Microbial sensitivity tests
  • 相关文献

参考文献5

  • 1Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol, 2004, 42( 1 ): 242-249.
  • 2Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis, 2005, 192(1): 156-161.
  • 3Shin YK, Weinberg A, Spruance S, et al. Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis. J Infect Dis, 2003, 187(8): 1241-1245.
  • 4徐淑允,卞如濂,陈修.药理学试验方法.3版.北京:人民卫生出版社.2002,1729.
  • 5Losada I, Canizares A, Hellin T, et al. In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary? Enferm Infecc Microbiol Clin,2002, 20( 1 ): 25-27.

同被引文献18

  • 1侯建玲,侯建文,张爱华.阿奇霉素治疗早期梅毒失败2例[J].中国麻风皮肤病杂志,2006,22(7):602-603. 被引量:1
  • 2韩建德,陈木开,廖绮曼,王莉红,凌宏忠,涂裕英.生殖道沙眼衣原体对几种抗菌药物敏感性的研究[J].中华皮肤科杂志,2006,39(10):559-561. 被引量:33
  • 3王双,刘全忠.生殖支原体、解脲脲原体与泌尿生殖道症状的相关性研究[J].中国麻风皮肤病杂志,2007,23(6):465-467. 被引量:5
  • 4Marra CM, Colina AP, Godomes C, et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis, 2006, 194( 12): 1771-1773.
  • 5Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis, 2007, 45(5): 609-617.
  • 6Luna J. The safety, efficacy and immunogenicity of quadrivalent HPV (types 6/11/16/18) L1 virus-like-particle (VLP) vaccine in women aged 24 to 45, oral presentation of abstract, plenary session (PAl-04), 24th International Papillomavirus Conference and Clinical Workshop, (3-10 November 2007), Beijing: China
  • 7Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase Ⅲ double-blind, randomised controlled trial. Lancet, 2007, 369(9580): 2161-2170.
  • 8Hjorth SV, Bjomelius E, Lidbrink P, et at Sequence-based typing of Mycoplasma genitalium reveals sexual transmission. J Clin Microbiol, 2006, 44(6): 2078-2083.
  • 9Brad,shaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis, 2006, 193(3): 336-345.
  • 10Bradshaw CS, Jensen JS, Tabrizi SN, et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis, 2006, 12(7): 1149-1152.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部